Webcast CME Information
Release Date: August 2006
August 31, 2007
Learn why the treatment of diabetic retinopathy is on the threshold of the biggest change since the introduction of laser photocoagulation.
Recent advances in three areas—our understanding of the molecular mechanisms of the disease, advances in diagnostic instrumentation, and the emergence of medical treatments targeting the underlying pathophysiology—are converging upon the goal of achieving better vision outcomes for patients with diabetes. This activity will review current concepts in the pathophysiology of diabetic retinopathy, including diabetic macular edema; diagnostic techniques to detect the earliest stages of disease, including clinical and laboratory instrumentation; and review recent clinical trials of emerging pharmacological treatments.
This activity is intended for ophthalmologists, vision scientists, and other eyecare professionals.
Method of Participation and Obtaining CME Credit
This CME webcast is based upon educational content presented in a symposium held in Fort Lauderdale, Florida, on Friday, April 28, 2006.
The participant should: 1) view the content presented; 2) take the post test; 3) complete and submit the CME demographic and evaluation forms. This activity should take approximately 1.5 hours to complete. The expiration date for this activity is August 31, 2007. No credit will be granted after this date.
Continuing education credit is offered upon successful completion of the post test. Certificates will be issued to participants approximately 3 to 4 weeks after receipt of the CME registration and evaluation forms and successful completion of the post test with a passing score of 70% or better.
At the conclusion of this activity, the participant should be able to:
- Review the benefits and limitations of current treatments for diabetic retinopathy, including diabetic macular edema (DME)
- Describe the potential advantages and disadvantages of emerging treatments for diabetic retinal disorders in relation to underlying disease pathophysiology
- Discuss the value of using 2 internationally recognized classification scales to stage diabetic retinal disorders
- Compare and contrast methods to diagnose early diabetic retinopathy, including DME
- Discuss current concepts in the molecular mechanisms underlying diabetic retinal disorders
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Center for Accredited Healthcare Education (CAHE) and International Medical Press (IMP). CAHE is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The Center for Accredited Healthcare Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
In compliance with the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of CAHE and International Medical Press to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, CME provider staff, faculty, and planners) are expected to disclose any significant financial relationships with commercial interests over the past 12 months. CAHE also requires that faculty identify and reference off-label product or investigational uses of pharmaceutical and medical device products.
In accordance with the ACCME Standards for Commercial Support, parallel documents from other accrediting bodies, and the Center for Accredited Healthcare Education policy, identification and resolution of conflict has been made in the form of external peer review of educational content. The following disclosures have been made:
George A Williams, MD
Contract researcher: Alcon, Inc; Allergan, Inc; Novartis AG; Eli Lilly and Company; Genentech, Inc.
Consulting fee: Alcon, Inc; Allergan, Inc; Ophthalmic Mutual Insurance Company.
Dr Williams does not discuss investigational products or unlabeled uses of any commercial product in his presentation.
Jay S Duker, MD
Advisory board: Genentech, Inc.
Dr Duker discusses investigational medical devices and unlabeled/unapproved uses of intravitreal triamcinolone in his presentation.
Neil M Bressler, MD
Dr Bressler has no conflicts of interest to report.
Dr Bressler references unlabeled/unapproved uses of atorvastatin, dexamethasone, fluocinolone acetonide, triamcinalone acetonide, hyaluronidase, pegaptanib sodium, ranibizumab, bevacizumab, BIM 23190, epalrestat, zenarestat, midostaurin (PKC412), and ruboxistaurin mesylate in his presentation.
CME Provider and Educational Partner Staff
All staff of CAHE and IMP in a position to influence content have filed statements of disclosure with the CME provider. Any conflicts of interest were identified and resolved prior to their involvement in the planning of this activity. These disclosures are available for review by contacting Steve Weinman at 1 609 936 7915 or e-mail at email@example.com.
CAHE and IMP staffs have disclosed no conflicts of interest.
This activity is designed for healthcare professionals for educational purposes. Information and opinions offered by the faculty/presenters represent their own viewpoints. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information.
While the Center for Accredited Healthcare Education makes every effort to have accurate information presented, no warranty, expressed or implied, is offered. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
Commercial Support Acknowledgement
This activity is supported by an educational grant from Eli Lilly and Company.